Lung Cancer

Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications.

The chemistry behind selective KRAS G12C therapies and potential future research avenues were discussed in a recently released journal article.

In a recent study, researchers identified several factors associated with the development of pneumonitis with therapies targeting non–small-cell lung cancer.

Considerations in first-line and second-line therapy selection in non–small-cell lung cancer without genetic alterations were presented in a recent review article.

Although generally mild adverse events are associated with the use of immune checkpoint inhibitors for non–small-cell lung cancer, occasionally serious complications may result.

A recent review of the various approaches to developing new therapeutic drugs to treat KRAS-harboring tumors also discusses emerging drugs.

Molecular testing of early-stage non–small-cell lung cancer is recommended after clinical trial results demonstrate osimertinib is effective for patients with EGFR-harboring tumors.

A retrospective cohort study demonstrates patients with inoperable non–small-cell lung cancer receiving aspirin have improved overall survival compared with patients not receiving aspirin.

A recent review of case reports of patients with non–small-cell lung cancer receiving immune checkpoint therapy finds neurologic adverse events are a rare but concerning side effect.

Patients who take immune checkpoint inhibitors experience a small number of severe side effects, although the majority of them recover with treatment.